openPR Logo
Press release

Cirrhosis Management Market Growth, Forecast and Value Chain 2017-2027

10-25-2017 01:42 PM CET | Health & Medicine

Press release from: Future Market Insights

/ PR Agency: Future Market Insights
Cirrhosis Management Market Growth, Forecast and Value Chain

Cirrhosis causes the liver to shrink and harden which makes it difficult for the blood to flow into the portal vein in the liver .The liver becomes lumpy and hard, and will start to fail. Basically the liver is a hardy organ and has the ability to regenerate damaged cells. Cirrhosis develops in the liver when factors like chronic viral infections and alcohol are present for a long period of time. When this condition happens, the liver becomes scarred and injured. Scared liver cannot function properly which ultimately results in cirrhosis. The main causes of cirrhosis are excess alcohol consumption, hepatitis B, Hepatitis C and non-alcoholic fatty liver diseases.

Browse Full Report With ToC @ https://www.futuremarketinsights.com/reports/cirrhosis-management-market#tbl-content

There are mainly two stages of cirrhosis: compensated and decompensated. In compensated cirrhosis, there are no signs of symptoms which means there is a still presence of healthy liver cells that can meet the body needs. Whereas, decompensated cirrhosis causes symptoms such as fluid will build up in the belly (ascites), toxins will build up in the blood causing confusion, occurrence of gallstones, etc. Chances of these problems can be reduced by keeping a healthy weight, eating a low fat diet, not smoking, sticking to the treatments, not drinking. Treatments like medications, regular doctor visits and lifestyle changes can sometimes prevent or delay the further damaging of the liver. According to the National Institute of Health (NIH), cirrhosis is the 12th leading cause of death due to the diseases in the United States. Also it is estimated that cirrhosis occurs in 2 individuals per 100,000 individuals. Cirrhosis is more common in men than women.

Cirrhosis Management Market: Drivers and Restraints

The appropriate method for cirrhosis management is of major importance. Thus it is expected to be the prime factor driving growth of global cirrhosis management. Increasing prevalence of disease such as non-alcoholic fatty liver diseases is fueling the global cirrhosis management market growth. Moreover, the growing geriatric population has also lead to the significant addition in the global cirrhosis management market. However the lack of low treatment rate due to absence of signs and symptoms of cirrhosis are limiting the growth of global cirrhosis management market.

Cirrhosis Management Market: Overview

Based on the treatment type, the global cirrhosis management market is segmented into treating cirrhosis causes, symptomatic treatment, treatment to avoid complications and liver transplantation. Based on disease indication, the global cirrhosis management market is segmented into alcoholic liver cirrhosis and non-alcoholic liver cirrhosis. Based on end user, the global cirrhosis management market is segmented into hospitals, ambulatory surgical centers, research institutes, dialysis centers, clinics and others.

Cirrhosis Management Market: Regional Outlook

Geographically, global cirrhosis management market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is expected to dominate global cirrhosis management market over the forecast period due to high prevalence of liver cirrhosis diseases. Western Europe is expected to be the second largest market for cirrhosis management.

Request For Report sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5045

Cirrhosis Management Market: Key Players

Some of the players identified in global cirrhosis management market include B. Braun Medical Inc., Alliancells Bioscience Corporation Limited, Conatus Pharmaceuticals Inc., Stempeutics Research Pvt Ltd, Merck Sharp & Dohme Corp., Epic Research & Diagnostics, Inc., Theravance Biopharma R&D, Inc., NovaShunt AG among others

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

Contct Us

Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cirrhosis Management Market Growth, Forecast and Value Chain 2017-2027 here

News-ID: 785604 • Views:

More Releases from Future Market Insights

Extruded Snacks Market to Reach USD 170.3 Billion by 2035 Amid Health and Convenience Revolution
Extruded Snacks Market to Reach USD 170.3 Billion by 2035 Amid Health and Conven …
A new market analysis released today projects the global extruded snacks market to surge from an estimated USD 89.9 billion in 2025 to USD 170.3 billion by 2035, demonstrating a robust Compound Annual Growth Rate (CAGR) of 6.6%. The market is set to deliver an impressive absolute dollar opportunity of USD 80.4 billion over the forecast period, driven by a global consumer shift towards convenient, shelf-stable, and healthier snack options. The
Global Banana Flakes Market Soars to USD 876.1 million by 2035, Driven by Health & Clean-Label Trends
Global Banana Flakes Market Soars to USD 876.1 million by 2035, Driven by Health …
A new market analysis reveals the global banana flakes market is set to expand significantly, projecting a robust Compound Annual Growth Rate (CAGR) of 4.6% from 2025 to 2035. The market, valued at USD 559.6 million in 2025, is forecast to reach USD 876.1 million by 2035, fueled by a rising consumer preference for natural, gluten-free, and plant-based ingredients in daily food choices. This press release offers a detailed look into
Confectionery Fillings Market Sweetens Global Outlook, Projected to Reach USD 2.2 Billion by 2035
Confectionery Fillings Market Sweetens Global Outlook, Projected to Reach USD 2. …
The global confectionery fillings market is poised for significant growth, with a new market analysis revealing a robust expansion fueled by a surge in consumer demand for innovative flavors and indulgent textures. According to the analysis, the market is estimated at USD 1381.2 million in 2025 and is projected to reach USD 2207.4 million by 2035, exhibiting a healthy compound annual growth rate (CAGR) of 4.8% during the forecast period. The
Water Softener Market to Skyrocket to USD 8.7 Billion by 2035, Driven by Smart Technology and Hard Water Crisis
Water Softener Market to Skyrocket to USD 8.7 Billion by 2035, Driven by Smart T …
A new market analysis reveals the global water softener market is poised for significant expansion, with a forecasted value of USD 8.7 billion by 2035. The report, covering the period from 2025 to 2035, projects a robust Compound Annual Growth Rate (CAGR) of 8.3%, up from an estimated USD 3.9 billion valuation in 2025. This surge is fueled by a combination of factors, including increasing consumer awareness of hard water's

All 5 Releases


More Releases for Cirrhosis

Cirrhosis Pipeline: Novel Antifibrotic Therapies and Regenerative Approaches Red …
The treatment landscape for cirrhosis, a progressive liver condition marked by fibrosis and compromised liver function, is witnessing a transformative shift as biopharmaceutical companies advance beyond symptomatic management to target the underlying causes of liver damage. With no approved therapies to reverse established fibrosis, there is a growing focus on antifibrotic agents, hepatoprotective compounds, and regenerative therapies that aim to halt or reverse disease progression. Companies like Ocera Therapeutics, Gilead
Liver Cirrhosis - Drug Pipeline Landscape, 2023
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known as fibrosis as a result of liver disease damage. Cirrhosis is caused by alcoholic liver disease, non-alcoholic steatohepatitis (NASH), chronic hepatitis B, and chronic hepatitis C. To Remain 'Ahead' Of Your Competitors, Request for A Sample: https://www.globalinsightservices.com/request-sample/GIS31149 Cirrhosis symptoms emerge slowly until liver
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2023
New York, Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. Read more about Primary Biliary Cirrhosis - Drug Pipeline here: https://www.globalinsightservices.com/reports/primary-biliary-cirrhosis-primary-biliary-cholangitis-drug-pipeline-landscape-2022/ Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed
Liver Cirrhosis - Drug Pipeline Landscape, 2023
New York, Global Insight Services have recently published a report on Liver Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. Read more about this report: https://www.globalinsightservices.com/reports/liver-cirrhosis-drug-pipeline-landscape-2023/ Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed and are destroyed eventually. Read more about Primary Biliary Cirrhosis - Drug Pipeline
Global Liver Cirrhosis Market Growth 2018-2023
Market Research Report Store offers a latest published report on Liver Cirrhosis Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Liver Cirrhosis players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Liver Cirrhosis with respect to individual